» Articles » PMID: 19660509

Human Leukocyte Antigen-G is Expressed in Advanced-stage Ovarian Carcinoma of High-grade Histology

Overview
Journal Hum Immunol
Date 2009 Aug 8
PMID 19660509
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

HLA-G is a nonclassical MHC class I molecule with restricted normal tissue distribution, but whose expression is induced in pathologic situations such as cancer. In regard to the its immunosuppressive properties, it has been suggested that HLA-G could be a way for tumors to escape immunosurveillance. HLA-G has been described in almost all types of cancer, whatever their origins. Ovarian cancer is the second leading cause of death among women with gynecologic cancers, after breast cancer. The high mortality rate of this pathology is linked to its late discovery resulting from discreet symptomatology at early stages and the current paucity of highly sensitive and specific biomarkers. The aim of the present study was to analyze, in a French, retrospectively based study, whether HLA-G could be a marker for the detection of ovarian cancer and the prediction of clinical evolution. For this purpose, we looked for HLA-G expression in ovarian carcinoma lesions from low to high grade and stage, and we showed that HLA-G is selectively expressed in advanced-stage disease of high-grade histology.

Citing Articles

Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects.

Wang S, Wang J, Xia Y, Zhang L, Jiang Y, Liu M J Transl Med. 2024; 22(1):130.

PMID: 38310272 PMC: 10838004. DOI: 10.1186/s12967-024-04938-w.


EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma.

Vo D, Liu Y, Sood A, Rezvani K, Jazaeri A, Liu J Cancer Biomark. 2024; 39(4):289-298.

PMID: 38250760 PMC: 11091604. DOI: 10.3233/CBM-230200.


Killer instincts: natural killer cells as multifactorial cancer immunotherapy.

Nersesian S, Carter E, Lee S, Westhaver L, Boudreau J Front Immunol. 2023; 14:1269614.

PMID: 38090565 PMC: 10715270. DOI: 10.3389/fimmu.2023.1269614.


Unveiling the Immunogenicity of Ovarian Tumors as the Crucial Catalyst for Therapeutic Success.

Rodriguez G, Yakubovich E, Vanderhyden B Cancers (Basel). 2023; 15(23).

PMID: 38067396 PMC: 10705691. DOI: 10.3390/cancers15235694.


Roles of HLA-G/KIR2DL4 in Breast Cancer Immune Microenvironment.

Zheng G, Jia L, Yang A Front Immunol. 2022; 13:791975.

PMID: 35185887 PMC: 8850630. DOI: 10.3389/fimmu.2022.791975.